Cancer

 

Clinical courses

 

Clinical courses

  • 3 December 2017

    Regional Centre for Biotechnology opens for M.Pharm / M.Sc professionals for cancer research

    Regional Centre for Biotechnology (RCB), an institution of education, training and research is established by the Department of Biotechnology, Government of India under the auspices of UNESCO. The Centre will focus on cooperatively working towards shared biotechnology growth in the Asia-Pacific Region. Regional interactions in biotechnology will promote co-operation amongst the countries to develop necessary infrastructure and capacity building for economic benefit of our societies.

  • 25 September 2017
    Vacancies for Ph.D Fellowships at Central Inter-Disciplinary Research Facility

    Central Inter-Disciplinary Research Facility (CIDRF) is a Department of Scientific & Industrial Research, Govt. of India recognized research center inaugurated in 2012, to foster research emanating from ‘bed side’ to ‘bench’ and back to ‘bed side’ enabled by its association to two medical (MGMCRI, SSSMCRI) and one dental (IGIDS) institution with hospitals.  CIDRF is intended to be an inter-disciplinary open forum for interaction between scientists and clinicians taking medical research to molecular levels so that clinical practice gets the strongest evidence base and support.

    Post : “CIDRF-Dr.Vany Adithan Ph.D Fellowship”

  • In India, oncology treatment generally covers lakhs, particularly with certain lung, prostate and breast cancer drugs evaluated on a lakh per dose in some cases. Regulatory systems, diagnosis, treatment infrastructure and funding mechanisms must be tailored to the needs of patients.

  • 19 March 2017
    ADVANCEMENTS IN PHARMACOLOGY AND ITS EFFECT ON HEALTH CARE INDUSTRY

    { DOWNLOAD AS PDF }

    ABOUT AUTHORS
    Neha Bala, Naresh Mali    *
    Institute of Health Management Research, Jaipur
    Rajasthan,  India
    malinaresh888@gmail.com

    The tremendous pharmacological advances witnessed during the last few decades have revolutionize virtually all aspects of modern life,including our understanding of disease.New drugs have contributed significantly to the economic impact of new developments in health care.With recognition that the pace of pharmacological development and acquiring of new knowledge will certainly accelerate in the coming years,let us consider what these advances might hold for Pharmacological advancement,Pharmacology is the branch of biology concerned with the study of drug action, where a drug can be broadly defined as any natural, or endogenous (from within body) molecule which exerts a biochemical and/or physiological effect on the cell, tissue, organ, or organism

  • 20 January 2017
    NANO-PARTICLES CONTAINING ANTICANCER DRUG

    { DOWNLOAD AS PDF }

    ABOUT AUHTORS
    Debpratim Chakraborty*, Nisha Lama Yolmo
    Department of Pharmaceutical tech,
    Jadavpur University,
    Kolkata, West Bengal, India
    *debpratim008@gmail.com

    ABSTRACT:
    Now a day in medical science and researches, cancer is one of the most life threatening disease but unfortunately still now we have no medical treatment for procurement of this disease. The pathology is not totally clear but according to medical evidence if we consider genes then we must agree that oncogene and tumor suppressor genes are mainly responsible. There are some risk factor also consider which may leads to cancer. The conventional treatments are surgery, Radio-therapy and chemo therapy but the real fact is none of the above mentioned treatment is enough for procurement of cancer and that’s why now scientist and researchers are thinking about nan-technology. NCI has identified that nano-technology have the potential to make paradigm changing impacts on the detection, treatment and prevention of cancer.  There are different strategies for cancer therapy using nano-particles like targeted and non-targeted nano-particles. Different studies show that the side effect of doxorubicine (an anticancer drug) can be minimizing by nano-technology, which also reduce the multi drug resistance. Nano-sphere and Nano-capsule of anti-steroid 4-hydroxytamoxifen RU reduce estrogen dependent tumor. Dendritic nano-technology with 5-fluro Uracil decreases the drug clearance and increase the therapeutic time. Methotrixate incorporated dendritic polymer target the folic acid receptor. Camptothecin loaded nano-particles show longer plasma retention, high and longer tumor localization. Nano-particles prepared by poly-lactic-co-glycolide increase the half life of Cisplatin. Paclitaxel, a microtubule-stabilizing agent that promotes polymerization of tubulin causing cell death by disrupting the dynamics necessary for cell division, is effective against a wide spectrum of cancers. Miscellaneous agent like Arsenic trioxide, Butyric Acid, Diethylene-triamine-Acetic acid show more prominent activity. Recent development in nanoparticle-based combination therapy have shown several unique features that are untenable in traditional chemotherapy. Drug combinations can now be optimizedand cleverly delivered in a more effective way.

  • Pembrolizumab (trade name: Keytruda) was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy also for these patients.

  • An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute.

  • 26 October 2016
    IN-VITRO ANTIPROLIFERATIVE ACTIVITY OF M. AZEDARACH

    { DOWNLOAD AS PDF }

     ABOUT AUHTORS
    Deepak Chowrasia1*, Nisha Sharma1, Mohammad Arshad2
    1 University Institute of Pharmacy,
    CSJM University, Kanpur, U.P., India
    2Molecular Endocrinology Lab, Department of Zoology,
    Lucknow University, Lucknow, U.P., India
    * chowrasia.deepak@gmail.com

    ABSTRACT
    Preliminary screening of different crude extract of. M. azedarach was evaluated against human cancer cell lines viz. MCF-7 (breast cancer), SaOS-2 (osteosarcoma), and A431 (epidermoid carcinoma) to search for better herbal based anticancer agent. Solvents used were water, methanol, ethanol, n-butanol, & n-hexane. It has been found that among solvents, methanolic extract of M. azedarach shows comparatively superior activity suggesting presence of phytoconstituents comprising polar functionalities.

Subscribe to Cancer

Subscribe with us




 


 

 

Do Not Forget to Verify

(Click on Subscription link in your inbox)

--------

whatsapp

 

Also Join:  youtube  telegram

admission for pharma MBA

 

GPAT

Jobs by Category

Production Jobs

R&D Jobs

F&D Jobs

Sales & Marketing

QA Jobs

QC Jobs

Faculty Jobs

CRO Jobs

DRA Jobs

IPR Jobs

IT Jobs

Packaging Alerts

Hospital Pharmacist